Drugs / Renvastinib
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06839105 Background | Feb 2025 → Apr 2028 expected | colorectal cancer, non-small cell lung carcinoma, renal cell adenocarcinoma | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Renvastinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06839105 ↗ |